Table 3.
Comparison of patients’ clinical characteristics by BRCA mutations and serum level of basal E2
| BRCA (+) | BRCA (−) | p‡ | |||
|---|---|---|---|---|---|
| High E2 (>48 pg/ml) (n=10) | Low E2 (≤48 pg/ml) (n=19) | High E2 (>48 pg/ml) (n=11) | Low E2 (≤48 pg/ml) (n=56) | ||
| Age (years) | 31.4±3.1a,b,c | 34.7±4.9a | 35.5±3.3b | 35.2±4.4c | a: p=0.05, b: p=0.01, c: p=0.02 |
| Parity ≥1 | 9.8% | 18.5% | 12.5% | 9.3% | NS |
| BMI (Kg/m2) | 20.8±1.9 | 22.0±1.4 | 23.2±3.9 | 22.7±3.3 | NS |
| Age at menarche (years) | 13.6±1.3d | 12.1±1.2d | 12.6±0.7 | 12.7±1.7 | d: p=0.02 |
| Family history of breast/ovarian cancer* | 50.0% | 42.1% | 40.0% | 27.1% | NS |
| History of infertility† | 15.4% | 11.1% | 12.5% | 15.9% | NS |
| Cancer | |||||
| Stage | NS | ||||
| ≤ II | 77.8% | 100.0% | 100.0% | 93.6% | |
| III | 22.2% | 0.0% | 0.0% | 6.4% | |
| ERα | 77.8%e | 35.7%e | 90.0% | 92.6% | e: p=0.04 |
| PR | 66.7%f | 25.0%f | 77.8% | 82.0% | f: p=0.04 |
| Her2/neu | 25.0% | 20.0% | 37.5% | 33.3% | NS |
| Basal FSH (mIU/ml) | 5.0±3.5g,h,i | 7.4±3.5g | 7.3±3.6h | 7.3±3.0i | g: p=0.02, h: p=0.05, i: p=0.008 |
Abbreviation: ERα, estrogen receptor α; PR, progesterone receptor; FSH, follicle stimulating hormone
*
History of breast/ovarian cancer in first-degree relatives
†
Any history of receiving fertility treatment.
‡
Analyzed with Kruskal-Wallis test